Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos

Krabbe disease is a sphingolipidosis characterized by the genetic deficiency of the acid hydrolase β-galactosylceramidase (GALC). Most of the studies concerning the biological role of GALC performed on Krabbe patients and Galc-deficient twitcher mice (an authentic animal model of the disease) indica...

Full description

Bibliographic Details
Main Authors: Jessica Guerra, Mirella Belleri, Giulia Paiardi, Chiara Tobia, Davide Capoferri, Marzia Corli, Elisa Scalvini, Marco Ghirimoldi, Marcello Manfredi, Rebecca C. Wade, Marco Presta, Luca Mignani
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:Computational and Structural Biotechnology Journal
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S200103702400076X
_version_ 1827291916998279168
author Jessica Guerra
Mirella Belleri
Giulia Paiardi
Chiara Tobia
Davide Capoferri
Marzia Corli
Elisa Scalvini
Marco Ghirimoldi
Marcello Manfredi
Rebecca C. Wade
Marco Presta
Luca Mignani
author_facet Jessica Guerra
Mirella Belleri
Giulia Paiardi
Chiara Tobia
Davide Capoferri
Marzia Corli
Elisa Scalvini
Marco Ghirimoldi
Marcello Manfredi
Rebecca C. Wade
Marco Presta
Luca Mignani
author_sort Jessica Guerra
collection DOAJ
description Krabbe disease is a sphingolipidosis characterized by the genetic deficiency of the acid hydrolase β-galactosylceramidase (GALC). Most of the studies concerning the biological role of GALC performed on Krabbe patients and Galc-deficient twitcher mice (an authentic animal model of the disease) indicate that the pathogenesis of this disorder is the consequence of the accumulation of the neurotoxic GALC substrate β-galactosylsphingosine (psychosine), ignoring the possibility that this enzyme may exert a wider biological impact. Indeed, limited information is available about the effect of GALC downregulation on the cell lipidome in adult and developing organisms. The teleost zebrafish (Danio rerio) has emerged as a useful platform to model human genetic diseases, including sphingolipidoses, and two GALC co-orthologs have been identified in zebrafish (galca and galcb). Here, we investigated the effect of the competitive and irreversible GALC inhibitor β-galactose-cyclophellitol (GCP) on the lipid profile of zebrafish embryos. Molecular modelling indicates that GCP can be sequestered in the catalytic site of the enzyme and covalently binds human GALC, and the zebrafish Galca and Galcb proteins in a similar manner. Accordingly, GCP inhibits the β-galactosylceramide hydrolase activity of zebrafish in vitro and in vivo, leading to significant alterations of the lipidome of zebrafish embryos. These results indicate that the lack of GALC activity deeply affects the lipidome during the early stages of embryonic development, and thereby provide insights into the pathogenesis of Krabbe disease.
first_indexed 2024-04-24T12:47:13Z
format Article
id doaj.art-c98712cfb14b4da3a4a44f64229c80dd
institution Directory Open Access Journal
issn 2001-0370
language English
last_indexed 2024-04-24T12:47:13Z
publishDate 2024-12-01
publisher Elsevier
record_format Article
series Computational and Structural Biotechnology Journal
spelling doaj.art-c98712cfb14b4da3a4a44f64229c80dd2024-04-07T04:35:26ZengElsevierComputational and Structural Biotechnology Journal2001-03702024-12-012313971407Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryosJessica Guerra0Mirella Belleri1Giulia Paiardi2Chiara Tobia3Davide Capoferri4Marzia Corli5Elisa Scalvini6Marco Ghirimoldi7Marcello Manfredi8Rebecca C. Wade9Marco Presta10Luca Mignani11Department of Molecular and Translational Medicine, University of Brescia, Brescia, ItalyDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, ItalyDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Molecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies, Germany; Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Alliance, Heidelberg, GermanyDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, ItalyDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, ItalyDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, ItalyDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, ItalyDepartment of Translational Medicine, University of Piemonte Orientale, Novara, Italy; Center for Allergic and Autoimmune Diseases, University of Piemonte Orientale, Novara, ItalyDepartment of Translational Medicine, University of Piemonte Orientale, Novara, Italy; Center for Allergic and Autoimmune Diseases, University of Piemonte Orientale, Novara, ItalyMolecular and Cellular Modeling Group, Heidelberg Institute for Theoretical Studies, Germany; Zentrum für Molekulare Biologie der Universität Heidelberg (ZMBH), DKFZ-ZMBH Alliance, Heidelberg, Germany; Interdisciplinary Center for Scientific Computing (IWR), Heidelberg University, Heidelberg, GermanyDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Consorzio Interuniversitario Biotecnologie (CIB), Unit of Brescia, ItalyDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy; Corresponding author.Krabbe disease is a sphingolipidosis characterized by the genetic deficiency of the acid hydrolase β-galactosylceramidase (GALC). Most of the studies concerning the biological role of GALC performed on Krabbe patients and Galc-deficient twitcher mice (an authentic animal model of the disease) indicate that the pathogenesis of this disorder is the consequence of the accumulation of the neurotoxic GALC substrate β-galactosylsphingosine (psychosine), ignoring the possibility that this enzyme may exert a wider biological impact. Indeed, limited information is available about the effect of GALC downregulation on the cell lipidome in adult and developing organisms. The teleost zebrafish (Danio rerio) has emerged as a useful platform to model human genetic diseases, including sphingolipidoses, and two GALC co-orthologs have been identified in zebrafish (galca and galcb). Here, we investigated the effect of the competitive and irreversible GALC inhibitor β-galactose-cyclophellitol (GCP) on the lipid profile of zebrafish embryos. Molecular modelling indicates that GCP can be sequestered in the catalytic site of the enzyme and covalently binds human GALC, and the zebrafish Galca and Galcb proteins in a similar manner. Accordingly, GCP inhibits the β-galactosylceramide hydrolase activity of zebrafish in vitro and in vivo, leading to significant alterations of the lipidome of zebrafish embryos. These results indicate that the lack of GALC activity deeply affects the lipidome during the early stages of embryonic development, and thereby provide insights into the pathogenesis of Krabbe disease.http://www.sciencedirect.com/science/article/pii/S200103702400076XLipidomicsGalactosylceramidaseKrabbe diseaseMolecular modelingZebrafish
spellingShingle Jessica Guerra
Mirella Belleri
Giulia Paiardi
Chiara Tobia
Davide Capoferri
Marzia Corli
Elisa Scalvini
Marco Ghirimoldi
Marcello Manfredi
Rebecca C. Wade
Marco Presta
Luca Mignani
Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos
Computational and Structural Biotechnology Journal
Lipidomics
Galactosylceramidase
Krabbe disease
Molecular modeling
Zebrafish
title Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos
title_full Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos
title_fullStr Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos
title_full_unstemmed Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos
title_short Impact of an irreversible β-galactosylceramidase inhibitor on the lipid profile of zebrafish embryos
title_sort impact of an irreversible β galactosylceramidase inhibitor on the lipid profile of zebrafish embryos
topic Lipidomics
Galactosylceramidase
Krabbe disease
Molecular modeling
Zebrafish
url http://www.sciencedirect.com/science/article/pii/S200103702400076X
work_keys_str_mv AT jessicaguerra impactofanirreversiblebgalactosylceramidaseinhibitoronthelipidprofileofzebrafishembryos
AT mirellabelleri impactofanirreversiblebgalactosylceramidaseinhibitoronthelipidprofileofzebrafishembryos
AT giuliapaiardi impactofanirreversiblebgalactosylceramidaseinhibitoronthelipidprofileofzebrafishembryos
AT chiaratobia impactofanirreversiblebgalactosylceramidaseinhibitoronthelipidprofileofzebrafishembryos
AT davidecapoferri impactofanirreversiblebgalactosylceramidaseinhibitoronthelipidprofileofzebrafishembryos
AT marziacorli impactofanirreversiblebgalactosylceramidaseinhibitoronthelipidprofileofzebrafishembryos
AT elisascalvini impactofanirreversiblebgalactosylceramidaseinhibitoronthelipidprofileofzebrafishembryos
AT marcoghirimoldi impactofanirreversiblebgalactosylceramidaseinhibitoronthelipidprofileofzebrafishembryos
AT marcellomanfredi impactofanirreversiblebgalactosylceramidaseinhibitoronthelipidprofileofzebrafishembryos
AT rebeccacwade impactofanirreversiblebgalactosylceramidaseinhibitoronthelipidprofileofzebrafishembryos
AT marcopresta impactofanirreversiblebgalactosylceramidaseinhibitoronthelipidprofileofzebrafishembryos
AT lucamignani impactofanirreversiblebgalactosylceramidaseinhibitoronthelipidprofileofzebrafishembryos